Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA's Anticounterfeiting Guidance Dodges Secrecy Concerns

This article was originally published in The Pink Sheet Daily

Executive Summary

In final guidance on the use of physical-chemical identifiers in solid oral dosage form drugs, FDA avoids addressing commenters' qualms about confidentiality.

You may also be interested in...

FDA recommends excipients be used as physical chemical identifiers to thwart drug counterfeiters

FDA has issued a draft guidance that recommends pharmaceutical manufacturers use "pharmacologically inactive" substances as physical-chemical identifiers (PCIDs) in solid oral dosage forms to fight drug counterfeiting. The draft guidance, entitled "Incorporation of Physical-Chemical Identifiers into Solid Oral Dosage Form Drug Products for Anticounterfeiting," notes that inks, pigments and flavors are some examples of substances that may be incorporated into solid dosage forms. The guidance notes that PCIDs should be "pharmacologically inactive so the ingredients can be treated as excipients." FDA recommends using "permissible direct food additives," including those affirmed as generally recognized as safe or those ingredients listed in the FDA Inactive Ingredient Guide to minimize toxicological risks. Various technologies that can be used to detect PCIDs include photolithography, holography, and laser scanning devices. The guide also addresses reporting or requesting approval to incorporate PCIDs into drug products as a postapproval change. Comments on the draft guidance are due Oct. 13

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Bayer/J&J's Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa

With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts